徐州医科大学附属医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma33 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer17 篇牵头论文
- 骨肉瘤Osteosarcoma9 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 尤文肉瘤Ewing sarcoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma37 篇牵头论文牵头 3 项开放试验
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
- 再生障碍性贫血Aplastic anaemia5 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
- 血友病 AHaemophilia A0 篇牵头论文
- 范可尼贫血Fanconi anaemia1 篇牵头论文
- 重症肌无力Myasthenia gravis13 篇牵头论文牵头 1 项开放试验
- 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
- 白塞病Behçet disease0 篇牵头论文
- IgA 肾病IgA nephropathy0 篇牵头论文
未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
牵头的论文5
- A prognostic nomogram for patients with III-IV nasopharyngeal carcinoma based on dynamic changes in the inflammatory and nutrition index.
- Collagen alpha-5(IV) chain activation by nuclear factor 1/C promotes nasopharyngeal carcinoma progression.
- Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis.
- Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
- A case of nasopharyngeal carcinoma presenting as Susac syndrome.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文4
- Esophageal squamous cell carcinoma derived sEV-PDL1 exhausts CD8+T cells to promote immunosuppression.
- USP33 is an integrin α6 deubiquitinase and promotes esophageal squamous cell carcinoma cell migration and metastasis.
- High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: A systematic review and meta-analysis.
- Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)5
- Correlation of SOAT1 and TREM1 expression with clinicopathological features and prognosis in esophageal squamous cell carcinoma
- 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
- 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
- 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
- 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 33 篇,占 0.2%。
徐州有 2 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- 分期
- I/II期
- 开始
- 2022-02
- 登记号
- NCT05323201
年龄 18 岁 至 70 岁(登记的条件)
牵头:徐州医科大学附属医院徐州
- 正在招募β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
- 分期
- II期
- 开始
- 2025-12
- 登记号
- NCT07317414
年龄 18 岁 至 75 岁(登记的条件)
牵头:北京协和医院;另有 2 家列出的医院为研究中心北京、南京、徐州
- 正在招募ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- 分期
- II期
- 开始
- 2025-06
- 登记号
- NCT07327034
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙
- 正在招募A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06427941
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文33
- Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity.
- PPP1CA promotes hepatocellular carcinoma progression in a YAP1-dependent way.
- PDLIM2 deficiency mediated by PBXIP1 promotes the proliferation of HCC cells through reducing the polyubiquitination and degradation of TRIM27.
- Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application.
- USP13 Facilitates the Proliferation of Hepatocellular Carcinoma Cells by Reducing K48/63-Linked Polyubiquitination and Degradation of PRPF6.
- Symptom Cluster Trajectories Among Patients With Hepatocellular Carcinoma After Partial Hepatectomy: A Longitudinal Study.
- A preoperative prediction model for microvascular invasion in hepatocellular carcinoma based on inflammatory biomarkers.
- FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma.
- Identification of TSEN15 as a novel biomarker for diagnosis, prognosis, and immune infiltration in hepatocellular carcinoma.
- Impact of frailty on the long-term prognosis of the elderly with hepatocellular carcinoma treated with transarterial chemoembolization.
- Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy.
- A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
- RABIF promotes hepatocellular carcinoma progression through regulation of mitophagy and glycolysis.
- SIAH2 suppresses c-JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma.
- Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- NUP37 accumulation mediated by TRIM28 enhances lipid synthesis to accelerate HCC progression.
- The high expression of ADRM1 in hepatocellular carcinoma is closely related to tumor immune infiltration and is regulated by miR-891a-5p.
- Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma.
- Ubiquitin ligase NEDD4 promotes the proliferation of hepatocellular carcinoma cells through targeting PCDH17 protein for ubiquitination and degradation.
- Nucleolin malonylation as a nuclear-cytosol signal exchange mechanism to drive cell proliferation in Hepatocarcinoma by enhancing AKT translation.
- Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.
- Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.
- A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
- SIAH1/CTR9 axis promotes the epithelial-mesenchymal transition of hepatocellular carcinoma.
- HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors.
- The prognostic value of the tertiary lymphoid structure in gastrointestinal cancers.
- Transarterial Chemoembolization plus Apatinib with or without Camrelizumab for the Treatment of Advanced HBV-related Hepatocellular Carcinoma.
- Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis.
- Transcriptional regulator CTR9 promotes hepatocellular carcinoma progression and metastasis via increasing PEG10 transcriptional activity.
- Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
- Circular RNA circ_0021093 regulates miR-432/Annexin A2 pathway to promote hepatocellular carcinoma progression.
- ANP32A promotes the proliferation, migration and invasion of hepatocellular carcinoma by modulating the HMGA1/STAT3 pathway.
- Long non‑coding RNA ST8SIA6‑AS1 promotes the migration and invasion of hypoxia‑treated hepatocellular carcinoma cells through the miR‑338/MEPCE axis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 17 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
徐州有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
- 正在招募A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06427941
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙
- 正在招募A Phase 2 Clinical Study of ABSK061 and ABSK043
- 分期
- II期
- 开始
- 2024-11
- 登记号
- NCT06632262
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州
- 正在招募A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2022-01
- 登记号
- NCT05150691
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文17
- BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19-YBX1 Axis to Induce Immune Evasion in Gastric Cancer.
- Modeling the pre-metastatic niche of gastric cancer peritoneal metastasis under spatiotemporal resolution and investigating EVs-mediated immune suppression.
- Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.
- The association between psychological status and the development of early gastric cancer from atrophic gastritis.
- Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy.
- Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
- CA19‑9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy.
- The value of machine learning approaches in the diagnosis of early gastric cancer: a systematic review and meta-analysis.
- Effect of COP1 in Promoting the Tumorigenesis of Gastric Cancer by Down-Regulation of CDH18 via PI3K/AKT Signal Pathway.
- Clinicopathological and prognostic significance of elevated BTF3 expression in gastric cancer.
- TSPAN8 regulates EGFR/AKT pathway to enhance metastasis in gastric cancer.
- Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer.
- Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis.
- The expression of long non-coding RNA LINC01279 in gastric adenocarcinoma and its clinical significance.
- The adenosine-A2a receptor regulates the radioresistance of gastric cancer via PI3K-AKT-mTOR pathway.
- CD36: an emerging therapeutic target for cancer and its molecular mechanisms.
- Hypoxia-induced FOXO4/LDHA axis modulates gastric cancer cell glycolysis and progression.
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 11 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文9
- Bimetallic nanoconjugate hijack Fe-S clusters to drive a closed-loop cuproptosis-ferroptosis strategy for osteosarcoma inhibition.
- Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS/Ca2+/AMPK pathway.
- A meta-analysis of the efficacy and safety of first-line chemotherapeutic agents for osteosarcoma.
- Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression.
- Long non-coding RNA long intergenic non-coding 00641 mediates cell progression with stimulating cisplatin-resistance in osteosarcoma cells via microRNA-320d/myeloid cell leukemia-1 axis.
- Circular RNA_ANKIB1 accelerates chemo-resistance of osteosarcoma via binding microRNA-26b-5p and modulating enhancer of zeste homolog 2.
- ADCK1 is a potential therapeutic target of osteosarcoma.
- Anisotropic Truncated Octahedral Au with Pt Deposition on Arris for Localized Surface Plasmon Resonance-Enhanced Photothermal and Photodynamic Therapy of Osteosarcoma.
- Inactivation of ICAM1 inhibits metastasis and improves the prognosis of Ewing's sarcoma.
早期论文(2016–2020 年)5
- MicroRNA-150-5p inhibits proliferation and invasion of osteosarcoma cells by down-regulating VEGFA.
- Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma.
- Prognostic factors to survival of patients with chondroblastic osteosarcoma.
- Investigating ego modules and pathways in osteosarcoma by integrating the EgoNet algorithm and pathway analysis.
- MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 8 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 1 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 37 篇,占 2.2%。
徐州有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- 分期
- I/II期
- 开始
- 2023-12
- 登记号
- NCT06196255
年龄 18 岁 至 70 岁(登记的条件)
牵头:徐州医科大学附属医院徐州
- 即将招募Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
- 分期
- II期
- 开始
- 2025-05
- 登记号
- NCT06963866
年龄 18 岁 至 70 岁(登记的条件)
牵头:徐州医科大学附属医院徐州
- 即将招募Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
- 分期
- 不分期
- 开始
- 2025-07
- 登记号
- NCT07034755
年龄 18 岁 至 70 岁(登记的条件)
牵头:徐州医科大学附属医院徐州
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2025-12
- 登记号
- NCT07294625
年龄 18 岁 至 未注明(登记的条件)
牵头:江苏省人民医院(南医大一附院);另有 4 家列出的医院为研究中心上海、南京、徐州、西安、郑州
- 正在招募A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06083207
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安
- 正在招募A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- 分期
- III期
- 开始
- 2021-10
- 登记号
- NCT05020236
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春
- 即将招募A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- 分期
- 早期I期
- 开始
- 2026-01
- 登记号
- NCT07399444
年龄 18 岁 至 未注明(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 4 家列出的医院为研究中心南昌、天津、徐州、武汉、郑州
- 即将招募Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07569757
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文37
- LncRNA H19-Encoded Micropeptide altH19 Promotes DNA Replication and Mitosis in Myeloma Cells by Enhancing the Phosphorylation of CDK2 at Threonine 160.
- Advances in NK cell therapy for multiple myeloma.
- Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse.
- ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1.
- Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.
- Identification of a new micropeptide altKLF4 derived from KLF4 that influences myeloma chemotherapeutic sensitivity.
- Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma.
- The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.
- Effect of metachronous primary and secondary solid cancers in patients with multiple myeloma: a retrospective study from a single-center.
- Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.
- Single-cell transcriptomics identifies PDIA4 as a marker of progression and therapeutic vulnerability in multiple myeloma.
- Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.
- Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.
- Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death.
- The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.
- Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.
- Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.
- Targeting GPRC5D for multiple myeloma therapy.
- A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.
- Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
- Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
- Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy.
- Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
- Novel c-Myc G4 stabilizer EP12 promotes myeloma cytotoxicity by disturbing NF-κB signaling.
- The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.
- A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
- Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
- Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
- Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.
- Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.
- Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.
- Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy.
- Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
- Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
- Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells.
- Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.
- Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
中文论文(未计入)11
- [Expression of GPRC5D in newly diagnosed patients with multiple myeloma detected by flow cytometry and its prognostic value].
- [Fever Characteristics and Biomarker Changes of CRS in Patients with Relapsed/Refractory Multiple Myeloma after CAR-T Cell Therapy].
- [Research Advances of Exosomes in Pathogenesis of Multiple Myeloma --Review].
- [The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy].
- [Effect of Hemoglobin on Efficacy of CAR-T Therapy in Patients with Multiple Myeloma].
- [The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment].
- [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA].
- [Hematological toxicity and risk factors in relapsed/refractory multiple myeloma patients after CAR-T therapy].
- [Analysis of Related Early Warning Indexes of Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Treatment].
- [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
- [Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
- Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
- Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
- Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头的开放试验
- 0
- 正在或即将招募
徐州有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06450067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州
- 正在招募Study of YK012 in B-cell Acute Lymphoblastic Leukemia
- 分期
- I/II期
- 开始
- 2024-09
- 登记号
- NCT06580301
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、广州、徐州、杭州、贵阳、长春
- 正在招募A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- 分期
- I期
- 开始
- 2024-09
- 登记号
- NCT06927466
年龄 3 岁 至 25 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、南昌、徐州、武汉、苏州
- 正在招募A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- 分期
- I/II期
- 开始
- 2023-02
- 登记号
- NCT05667506
年龄 3 岁 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心南京、南昌、合肥、天津、广州、徐州、武汉、重庆
- 正在招募A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- 分期
- I/II期
- 开始
- 2022-11
- 登记号
- NCT05579132
年龄 2 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
- Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
- A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Study of YK012 in B-cell Acute Lymphoblastic Leukemia
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
- The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)
- CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
徐州有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
- 分期
- 不分期
- 开始
- 2025-10
- 登记号
- NCT07499284
年龄 14 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院;另有 2 家列出的医院为研究中心徐州、杭州、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Complex association of mean corpuscular volume and outcomes in patients with aplastic anemia treated with cyclosporine A plus androgen or cyclosporine A alone.
- Identifying an AML Prognostic Model Using 10 Marker Genes from Single-Cell Transcriptome and Bulk Transcriptome Analysis.
- Red blood cell distribution width as a prognostic factor in patients with aplastic anemia treated with cyclosporin A plus androgen or cyclosporine A alone: a retrospective study.
- The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials.
- Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
这些数字背后的记录
牵头的论文2
- Disparity Analysis of Clinical Features and Prognostic Evaluation of Hemophagocytic Lymphohistiocytosis in Pediatric and Adult Patients: A Retrospective Multicenter Study of 525 Cases in HHLWG.
- A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
血友病 A
Haemophilia A2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 2 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 13 篇,占 2.6%。
徐州有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
- 分期
- 不分期
- 开始
- 2026-03
- 登记号
- NCT07413835
年龄 18 岁 至 80 岁(登记的条件)
牵头:徐州医科大学附属医院徐州
- 正在招募Myasthenia Gravis Registry in China
- 分期
- 未注明
- 开始
- 2024-02
- 登记号
- NCT06241521
年龄未注明(登记的条件)
牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文13
- Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.
- A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.
- Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.
- Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.
- Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse.
- Increased serum interleukin-41 correlates with disease severity in myasthenia gravis.
- Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
- Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
- The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis.
- Plasma C18:0-ceramide is a novel potential biomarker for disease severity in myasthenia gravis.
- Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.
- Increased Expression of CD95 in CD4+ Effector Memory T Cells Promotes Th17 Response in Patients with Myasthenia Gravis.
- IL-21 enhances STAT3/Blimp-1 signaling pathway in B cells and contributes to plasma cell differentiation in newly diagnosed patients with myasthenia gravis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
徐州有 3 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
- 正在招募A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- 分期
- II期
- 开始
- 2025-11
- 登记号
- NCT07121413
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- CSF3 aggravates acute exacerbation of pulmonary fibrosis by disrupting alveolar epithelial barrier integrity.
- Fatty acid metabolism-related genes in bronchoalveolar lavage fluid unveil prognostic and immune infiltration in idiopathic pulmonary fibrosis.
- PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model.
- Characterization of the heterogeneity of endothelial cells in bleomycin-induced lung fibrosis using single-cell RNA sequencing.
中文论文(未计入)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
白塞病
Behçet disease2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
徐州有 1 家医院列在白塞病下全国有 149 家医院列在白塞病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- 分期
- III期
- 开始
- 2023-11
- 登记号
- NCT06145893
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
徐州有 2 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
徐州医科大学附属医院
Affiliated Hospital of Xuzhou Medical University
徐州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。